Last Updated: November 16, 2026

Investigational Drug Information for Bucindolol

« Back to Dashboard


What is the drug development status for Bucindolol?

Bucindolol is an investigational drug.

There have been 3 clinical trials for Bucindolol. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 1994.

The most common disease conditions in clinical trials are Heart Failure, Atrial Fibrillation, and Heart Diseases. The leading clinical trial sponsors are National Heart, Lung, and Blood Institute (NHLBI), University of Oxford, and Royal Brompton & Harefield NHS Foundation Trust.

Recent Clinical Trials for Bucindolol
TitleSponsorPhase
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart FailureMedtronicPhase 2
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart FailureARCA Biopharma, Inc.Phase 2
Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart FailureUniversity of Oxford

See all Bucindolol clinical trials

Clinical Trial Summary for Bucindolol

Top disease conditions for Bucindolol
Top clinical trial sponsors for Bucindolol

See all Bucindolol clinical trials

Bucindolol Development Update, Patent Status, and Market Projection

Last updated: October 1, 2026

Bucindolol is an investigational, orally administered beta-adrenergic blocker that has not received FDA approval. Its development has been limited by negative or inconclusive late-stage results in broad heart-failure populations and the failure of a genotype-guided Phase 2b study. Bucindolol has no FDA-recognized commercial market, no Orange Book listing, and no active U.S. regulatory exclusivity. Under the current development record, the base-case 2026 market projection is $0.

What is the current development status of bucindolol?

Bucindolol development is effectively inactive based on the last publicly reported clinical record.

The drug was developed primarily for chronic heart failure with reduced ejection fraction. It combines beta-adrenergic blockade with vasodilatory activity and was intended to reduce sympathetic nervous-system activation without the degree of inverse agonism associated with some older beta blockers.

The principal development programs were:

Program Population Sponsor Result
BEST Advanced chronic heart failure National Institutes of Health and industry partners Did not produce a statistically significant reduction in all-cause mortality
GENETIC-AF Heart-failure patients selected by beta-1 adrenergic receptor genotype ARCA biopharma Stopped after interim analysis for lack of benefit on the primary endpoint
Earlier studies Hypertension and heart failure Multiple sponsors Did not establish a commercial regulatory path

The Beta-Blocker Evaluation of Survival Trial, or BEST, enrolled 2,708 patients with advanced chronic heart failure. Bucindolol did not significantly reduce all-cause mortality compared with placebo in the primary analysis, although secondary and subgroup findings supported further investigation in genetically defined populations (The Beta-Blocker Evaluation of Survival Trial Investigators, 2001).

ARCA biopharma later pursued a precision-medicine strategy based on the beta-1 adrenergic receptor Arg389 genotype. The GENETIC-AF study compared bucindolol with metoprolol in patients with heart failure and reduced ejection fraction. ARCA reported in 2018 that the trial was stopped for futility after an interim review. The primary endpoint was recurrent heart-failure hospitalization or cardiovascular death. The result removed the principal near-term route to approval.

When does bucindolol lose exclusivity?

Bucindolol has no FDA-approved product and therefore has no active FDA regulatory exclusivity period.

The original composition-of-matter patent term, if applicable to historical U.S. patents covering bucindolol or its hydrochloride salt, would have expired years ago based on the drug’s development history. Patent-term restoration cannot create meaningful current exclusivity for an unapproved molecule unless a qualifying patent and regulatory pathway remain in force. No such current U.S. exclusivity is evident from the drug’s regulatory status.

Exclusivity category Current status
FDA approval None
New chemical entity exclusivity None currently active
Orphan-drug exclusivity None identified
Pediatric exclusivity None identified
Orange Book listing None
Approved-product patent linkage None
Commercial generic market None

Historical patents could still matter in specific jurisdictions or for narrow formulations, but they do not establish a current U.S. commercial barrier without an approved reference product and enforceable claims.

What is the FDA regulatory status of bucindolol?

Bucindolol is not FDA approved for heart failure, hypertension, arrhythmia, or any other indication.

The drug has not generated an FDA-approved labeling package, approved dosage regimen, or reference listed drug designation. It therefore cannot be challenged through a conventional Abbreviated New Drug Application Paragraph IV certification against an Orange Book-listed reference product.

The practical regulatory position is:

  1. A sponsor would need to pursue a new drug application or another applicable approval pathway.
  2. Existing clinical data would not automatically support approval for a new sponsor.
  3. A genotype-guided label would require clinical evidence linking the biomarker-defined population to a clinically meaningful benefit.
  4. Prior Phase 3 and Phase 2b results would likely be central to FDA review of any re-development plan.

What did the BEST trial show?

The BEST trial failed to meet its primary mortality objective in the overall advanced-heart-failure population.

The study evaluated bucindolol in patients with severe chronic heart failure and left-ventricular systolic dysfunction. The overall results did not demonstrate a statistically significant reduction in all-cause mortality. The trial did show signals in selected subgroups, including patients with nonischemic cardiomyopathy, but these findings did not provide a sufficient basis for broad approval.

This result weakened the conventional commercial proposition: a beta blocker for the general heart-failure population. At the time, carvedilol, metoprolol succinate, and bisoprolol already had substantial clinical adoption, guideline support, and commercial availability.

Why did ARCA pursue a genotype-guided strategy?

ARCA’s development thesis was that beta-1 adrenergic receptor genotype could identify patients more likely to benefit from bucindolol than from metoprolol.

The relevant polymorphism involves the ADRB1 Arg389Gly variant. ARCA focused on patients carrying the Arg389Arg genotype, which was associated with differences in adrenergic signaling and beta-blocker response in earlier analyses.

GENETIC-AF was designed as a prospective pharmacogenomic comparison rather than a broad placebo-controlled efficacy trial. The strategic objectives were to:

  • identify a responder population;
  • differentiate bucindolol from established beta blockers;
  • support a precision-medicine label;
  • reduce the size of the target population required for commercialization.

The trial was stopped for futility in 2018. That decision materially reduced the probability of a near-term relaunch. A future program would likely require a new clinical rationale, a revised biomarker strategy, and prospective evidence overcoming the failed confirmatory development path.

What formulation patents protect bucindolol?

No commercially relevant formulation patent estate is evident from the drug’s unapproved status.

Bucindolol was developed as an oral small molecule, including bucindolol hydrochloride formulations. Potential patent categories historically associated with such a product could include:

  • composition-of-matter claims;
  • salt claims;
  • crystalline or solid-state forms;
  • tablet and capsule formulations;
  • methods of treating heart failure;
  • pharmacogenomic patient-selection methods.

These categories do not have equivalent commercial value. Composition claims would generally be the strongest, but they are also the oldest and most likely to have expired. Formulation and method-of-use claims could have later expiration dates, but their value would depend on claim scope, enforceability, regulatory relevance, and whether the claimed formulation or method is used by a future product.

Because bucindolol has no approved reference product, there is no current Orange Book patent listing linking a specific formulation or method-of-use patent to an FDA-approved label.

What patent litigation affects bucindolol?

No material current U.S. patent litigation involving bucindolol is evident from its discontinued development status.

There is no known active Paragraph IV litigation against a bucindolol reference product. There is also no established biosimilar or generic litigation pathway because bucindolol is a small molecule that lacks an approved reference product.

A future sponsor could face patent risk from historical patents if it sought approval in a jurisdiction where relevant claims remain enforceable. The larger practical risk would be regulatory and clinical rather than patent litigation. An applicant would need to recreate a viable approval strategy despite the negative BEST and GENETIC-AF outcomes.

How strong is the bucindolol patent estate?

The current patent estate is commercially weak for U.S. market purposes.

Patent-estate factor Assessment
Composition-of-matter protection Likely expired or commercially exhausted
Formulation protection No current FDA-linked barrier identified
Method-of-use protection Potentially relevant only to narrow future labels
Biomarker claims Could be strategically relevant, but clinical validation failed
Orange Book leverage None
Freedom to launch No approved reference product, but new approval is required
Litigation leverage Low absent an approved product and live blocking claims

The most valuable historical intellectual property was likely the combination of molecule-specific claims and clinical-use claims. The present value of that estate is limited because commercial approval was never achieved.

How does bucindolol compare with approved heart-failure beta blockers?

Bucindolol is commercially disadvantaged against established beta blockers.

Drug FDA status in heart failure Market position Differentiation
Carvedilol Approved Established generic standard Nonselective beta blockade with alpha-1 blockade
Metoprolol succinate Approved Established generic standard Beta-1 selective blockade
Bisoprolol Approved in several markets Established generic option Beta-1 selective blockade
Bucindolol Not approved No commercial position Proposed vasodilating and pharmacogenomic differentiation

The competitive hurdle is high. Any bucindolol relaunch would need to demonstrate either superior outcomes, a clinically validated responder population, or a meaningful tolerability advantage. A pharmacogenomic label alone would not guarantee adoption because physicians would need testing infrastructure, reimbursement, and evidence that genotype-guided treatment improves outcomes over low-cost generic beta blockers.

What is the market projection for bucindolol?

The current market projection is zero because there is no approved product, active commercial launch, or established reimbursement pathway.

A re-development scenario would produce a smaller and more specialized market than a conventional heart-failure product. The addressable population would be limited by:

  • patients with heart failure and reduced ejection fraction;
  • the proportion carrying the relevant ADRB1 genotype;
  • eligibility for beta-blocker treatment;
  • willingness to undergo genetic testing;
  • demonstrated superiority over generic alternatives.

A commercial model would also face price pressure. Carvedilol and metoprolol are available generically, and treatment guidelines already support beta-blocker use in appropriate HFrEF patients. Bucindolol would therefore require a premium clinical proposition.

Scenario Development assumption Commercial outlook
Base case No restart; no approval $0 revenue
Relaunch without biomarker differentiation New trials in broad HFrEF Low probability; intense generic competition
Genotype-guided relaunch New prospective biomarker trial and approval Niche opportunity, dependent on clinical validation
Successful premium launch Demonstrated outcome advantage and reimbursed testing Potential specialty cardiovascular product, but not a near-term forecast

The probability-adjusted value remains low because a sponsor would need to fund a new development program after two unfavorable late-stage outcomes. The expected market is not equivalent to the epidemiologic size of heart failure. It is the value of a clinically validated, reimbursed product after regulatory approval, and no such product currently exists.

Which companies are challenging bucindolol?

No active generic or biosimilar company is publicly positioned as a challenger to bucindolol because there is no approved bucindolol product to copy.

The relevant competitive pressure comes from manufacturers of generic carvedilol, metoprolol succinate, and bisoprolol. These products have established prescribing patterns and lower expected treatment costs. A bucindolol sponsor would compete against the standard of care rather than against an active Paragraph IV challenger.

ARCA biopharma was the principal modern developer associated with the genotype-guided program. The termination of GENETIC-AF removed the clearest identified corporate development pathway.

What licensing deals involve bucindolol?

No current major licensing transaction is central to the commercial outlook for bucindolol.

Earlier development involved industry collaboration and sponsor transitions, but the drug has not produced an approved product capable of generating royalty revenue or milestone payments. The lack of an active clinical program limits the value of licensing the molecule alone. A transaction would more likely require a complete package covering historical clinical data, intellectual property, regulatory correspondence, and a credible biomarker redevelopment plan.

Key Takeaways

  • Bucindolol is not FDA approved and has no Orange Book listing.
  • The BEST trial failed to show a significant reduction in all-cause mortality in the overall advanced-heart-failure population.
  • ARCA’s GENETIC-AF trial was stopped for futility in 2018.
  • No active U.S. regulatory exclusivity or commercial patent barrier is evident.
  • No Paragraph IV litigation, biosimilar risk, or generic-launch event currently applies.
  • Established generic beta blockers create a substantial pricing and adoption barrier.
  • The base-case 2026 revenue projection is $0.
  • Any future value would depend on a new, prospectively validated pharmacogenomic development program.

FAQs About Bucindolol Development and Commercial Potential

Is bucindolol available by prescription?

No. Bucindolol is not an FDA-approved prescription medicine and is not commercially available as an approved heart-failure treatment.

Did bucindolol fail clinical trials?

Bucindolol failed to meet the primary objective in the broad BEST heart-failure trial. A later genotype-guided study, GENETIC-AF, was stopped for futility.

Could bucindolol still be approved?

Approval is theoretically possible only through a new regulatory program supported by adequate clinical evidence. The existing development record does not support an immediate approval filing.

Is bucindolol a generic beta blocker?

No. Although it is a small-molecule beta blocker, no FDA-approved bucindolol reference product exists, so there is no conventional generic market.

Does bucindolol have biosimilar risk?

No. Biosimilars apply to biologic products. Bucindolol is a small molecule, and its relevant competitive risk would come from generic cardiovascular drugs and established beta blockers.

References

  1. The Beta-Blocker Evaluation of Survival Trial Investigators. (2001). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New England Journal of Medicine, 344(22), 1659-1667. https://doi.org/10.1056/NEJM200105313442201

  2. ARCA biopharma, Inc. (2018). ARCA biopharma announces topline results from the GENETIC-AF Phase 2B trial. Corporate press release.

  3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

  4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

  5. Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation, 145(18), e895-e1032. https://doi.org/10.1161/CIR.0000000000001063

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.